1. INTRODUCTION
1.1. Market Overview
1.2. Market Definition
1.3. Scope of the Study
1.4. Market Segmentation
1.5. Currency
1.6. Assumptions
1.7. Base and Forecast Years Timeline
1.8. Key Benefits for the Stakeholder
2. RESEARCH METHODOLOGY
2.1. Research Design
2.2. Research Processes
3. EXECUTIVE SUMMARY
3.1. Key Findings
4. MARKET DYNAMICS
4.1. Market Drivers
4.2. Market Restraints
4.3. Porter’s Five Forces Analysis
4.3.1. Bargaining Power of Suppliers
4.3.2. Bargaining Power of Buyers
4.3.3. Threat of New Entrants
4.3.4. Threat of Substitutes
4.3.5. Competitive Rivalry in the Industry
4.4. Industry Value Chain Analysis
4.5. Analyst View
5. GLOBAL DRUG API MARKET BY SYNTHESIS TYPE
5.1. Introduction
5.2. Biotech Drugs
5.3. Synthetic Drugs
6. GLOBAL DRUG API MARKET BY DRUG TYPE
6.1. Introduction
6.2. Generic Drug
6.3. Branded Drug
7. GLOBAL DRUG API MARKET BY APPLICATION
7.1. Introduction
7.2. Cardiology
7.3. Pulmonology
7.4. Oncology
7.5. Ophthalmology
7.6. Neurology
7.7. Orthopedics
7.8. Other Applications
8. GLOBAL DRUG API MARKET BY GEOGRAPHY
8.1. Introduction
8.2. North America
8.2.1. United States
8.2.2. Canada
8.2.3. Mexico
8.3. South America
8.3.1. Brazil
8.3.2. Argentina
8.3.3. Others
8.4. Europe
8.4.1. Germany
8.4.2. France
8.4.3. United Kingdom
8.4.4. Spain
8.4.5. Others
8.5. Middle East and Africa
8.5.1. Saudi Arabia
8.5.2. Israel
8.5.3. Others
8.6. Asia Pacific
8.6.1. China
8.6.2. Japan
8.6.3. South Korea
8.6.4. India
8.6.5. Others
9. COMPETITIVE ENVIRONMENT AND ANALYSIS
9.1. Major Players and Strategy Analysis
9.2. Market Share Analysis
9.3. Mergers, Acquisitions, Agreements, and Collaborations
9.4. Competitive Dashboard
10. COMPANY PROFILES
10.1. Teva Pharmaceutical Industries Ltd
10.2. Sun Pharmaceutical Industries Ltd
10.3. Novartis AG
10.4. Pfizer Inc.
10.5. Mylan NV
10.6. BASF SE
10.7. Boehringer Ingelheim GmbH
10.8. Dr. Reddy’s Laboratories Ltd
10.9. Lupin Ltd
10.10. Aurobindo Pharma